Last reviewed · How we verify
VCT220 Tablet
VCT220 Tablet is a small molecule that targets the PCSK9 protein to lower LDL cholesterol.
VCT220 Tablet is a small molecule that targets the PCSK9 protein to lower LDL cholesterol. Used for Hypercholesterolemia.
At a glance
| Generic name | VCT220 Tablet |
|---|---|
| Also known as | CX11 |
| Sponsor | Vincentage Pharma Co., Ltd |
| Drug class | PCSK9 inhibitor |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By binding to PCSK9, VCT220 Tablet inhibits the degradation of LDL receptors, leading to increased clearance of LDL cholesterol from the bloodstream. This results in a reduction in LDL cholesterol levels, which can help to slow the progression of atherosclerotic cardiovascular disease.
Approved indications
- Hypercholesterolemia
Common side effects
- Musculoskeletal pain
- Diarrhea
- Nausea
Key clinical trials
- A Food-Effect Study of CX11 in Healthy Participants (PHASE1)
- A Research Study of VCT220 in Adult Chinese Participants With Obesity (PHASE3)
- A Study of VCT220 in Participants With Hypertension and Obesity or Overweight (PHASE2)
- A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus (PHASE2)
- A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function (PHASE1)
- A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants (PHASE2)
- A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VCT220 Tablet CI brief — competitive landscape report
- VCT220 Tablet updates RSS · CI watch RSS
- Vincentage Pharma Co., Ltd portfolio CI